Buserelin
Hormonal / ClinicalAlso known as: Suprefact, Suprecur
Mechanism
A GnRH agonist similar to leuprolide and goserelin, widely used outside the US for prostate cancer, endometriosis, and IVF protocols. Available in unusually diverse forms — nasal spray, subcutaneous injection, and subcutaneous implant. Also extensively used in veterinary medicine for reproductive management in livestock and fish aquaculture.
Technical detail
Synthetic GnRH agonist nonapeptide — [D-Ser(tBu)6, Pro9-NHEt]-GnRH. D-amino acid substitution at position 6 (D-Ser(tBu)) confers resistance to endopeptidase degradation and increases GnRH receptor affinity ~20-50x vs. native GnRH. Pro9-NHEt C-terminal modification further enhances metabolic stability. Mechanism identical to other GnRH agonists: initial flare phase (1-2 weeks of increased LH/FSH and sex steroids) followed by GnRH receptor downregulation, desensitization, and gonadotropin suppression (medical castration). Formulations: intranasal (400 mcg 3x daily — one of few peptides with nasal delivery), SC injection (200-500 mcg daily), SC implant (6.3mg or 9.45mg, 2-3 month duration). Nasal bioavailability ~3%. In IVF: used for pituitary suppression to prevent premature LH surge during controlled ovarian hyperstimulation. Veterinary: induces ovulation in fish (salmon GnRH analog), synchronizes estrus in cattle.
Effects
Buserelin (Suprefact) is a synthetic GnRH agonist that, like other drugs in its class, initially stimulates and then downregulates pituitary GnRH receptors, leading to suppression of gonadotropin release and subsequent sex hormone reduction. The initial stimulation phase (flare) lasting 1-2 weeks causes transient increases in LH, FSH, and downstream testosterone or estradiol. Following receptor downregulation, sustained castrate-level hormone suppression is achieved and maintained with continued administration. Buserelin is available in multiple formulations that reflect its versatility: intranasal spray (requiring multiple daily doses due to low bioavailability of approximately 3%), subcutaneous injection (daily or depot), and subcutaneous implant (providing sustained release over 2-3 months). The intranasal route is unique among GnRH agonists and offers needle-free administration, though the requirement for 3 times daily dosing and variable absorption depending on nasal congestion are practical limitations. The implant formulation provides the most consistent drug delivery and is preferred for indications requiring reliable long-term suppression. Physiological effects mirror those of other GnRH agonists. In men, testosterone suppression leads to regression of androgen-dependent prostate tissue, with associated effects including hot flashes, gynecomastia, sexual dysfunction, and bone density loss. In women, estrogen suppression creates a reversible medical menopause with cessation of menses, hot flashes, vaginal dryness, and bone density concerns with prolonged use. In IVF protocols, buserelin prevents premature LH surges during controlled ovarian stimulation, allowing precise timing of oocyte maturation and retrieval.
Practitioner Guide
Buserelin is widely used in Europe, Canada, and parts of Asia but has never been FDA-approved in the United States, where leuprolide (Lupron), goserelin (Zoladex), and triptorelin (Trelstar) dominate the GnRH agonist market. This geographic gap means US-trained practitioners may be unfamiliar with buserelin despite its extensive global track record spanning over three decades. Its clinical efficacy is equivalent to leuprolide for all shared indications, and the choice between them is driven by formulation preference, availability, and regional prescribing habits. In reproductive medicine, buserelin remains a standard agent for pituitary downregulation in IVF long protocols, particularly in European clinics. The intranasal formulation is sometimes preferred by patients who want to avoid injections during the downregulation phase, though compliance with the 3-times-daily nasal spray schedule must be emphasized. For IVF short/antagonist protocols, GnRH antagonists like cetrorelix have largely replaced agonists, but buserelin retains a role in long-protocol and ultra-long-protocol stimulation regimens. Buserelin also has established veterinary applications, particularly in cattle and fish reproductive management. In bovine reproduction, buserelin is used to induce ovulation and improve conception rates in timed artificial insemination protocols. This veterinary use means that buserelin is manufactured at scale globally, contributing to its availability and lower cost in some markets compared to leuprolide. For practitioners encountering patients who have used buserelin abroad, the clinical effects and monitoring parameters are identical to those of leuprolide at equivalent gonadotropin-suppressive doses.
Research Summary
Tier 1 (robust evidence): Decades of clinical trial and real-world data confirm that buserelin achieves equivalent gonadotropin and sex hormone suppression compared to leuprolide and goserelin across indications including prostate cancer, endometriosis, precocious puberty, and IVF. Multiple randomized trials in IVF demonstrate comparable oocyte yield and pregnancy rates when buserelin is used for pituitary downregulation versus other GnRH agonists. Tier 2 (solid clinical data): Formulation-specific studies establish the pharmacokinetics of intranasal (approximately 3% bioavailability, requiring 300-900 mcg three times daily), subcutaneous injection, and implant delivery. Head-to-head comparisons with leuprolide in prostate cancer show no clinically meaningful differences in testosterone suppression, PSA response, or survival outcomes. Safety data are consistent with the GnRH agonist class, with no unique adverse effects attributable to buserelin specifically. Tier 3 (emerging/niche): Veterinary reproductive research continues to refine buserelin dosing protocols for timed AI in cattle, with large field trials supporting its efficacy in improving conception rates. Investigation of buserelin as a GnRH agonist trigger for final oocyte maturation in IVF (replacing hCG to reduce OHSS risk) has been studied but is less established than with other short-acting GnRH agonists. The commercial landscape for buserelin is stable in Europe and Asia but unlikely to expand to the US market given the entrenched position of leuprolide.